Cara Amanda Mathews, Nicoline Raashouu-Jensen, Carolyn K. McCourt, Filip Frühauf, Lucy Gilbert, Evelyn L. Fleming, Giorgio Valabrega, Noelle Cloven, Dominik Denschlag, Iwona Podzielinski, Ingrid A. Boere, Joseph Buscema, Kathryn Pennington, Nicole Suzanne Nevadunsky, Eirwen Murray Miller, Mark S. Shahin, Grace Antony, Laura Katherine Austin, Matthew A. Powell, Mansoor Raza Mirza. "Time to subsequent therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) receiving dostarlimab plus carboplatin-paclitaxel (DOST+CP) compared with pts receiving placebo plus CP (PBO+CP) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial.." Journal of Clinical Oncology (2025). https://doi.org/10.1200/jco.2025.43.16_suppl.5601